WYETH

Wyeth Limited has submitted to the Exchange copies of the following: 1. Newspaper advertisements of the Company giving notice of hearing of Petition for approval of the amalgamation of the Company with Pfizer Limited published in the Newspapers on August 07, 2014. 2. Newspaper advertisements of Pfizer Limited giving notice of hearing of Petition for approval of the amalgamation of the Company with Pfizer Limited in the Newspapers on August 07, 2014.

Wyeth Limited has informed the Exchange that the Trading Window for trading in the Equity shares of the Company is closed from January 11, 2014 to January 28, 2014, both days inclusive. "The company has provided details of trading window period as per Prohibition of Insider Trading Regulations, 1992 issued by SEBI wherein when the trading window is closed, the employees/directors shall not trade in the company s securities in such period".

Wyeth Limited has informed the Exchange that the Government of India on May 15, 2013 notified the Drugs (Prices Control) Order, 2013 bringing into effect a new drug pricing policy applicable to 348 formulations listed in the National List of Essential Medicines (NLEM). The Government has notified the ceiling price for 270 formulations as of now; with the balance notifications expected shortly. Companies have to implement the new price on the 46th day from the date of price notification. This will adversely impact the revenue and profitability of the Company. The above information has been incl

Wyeth Limited has submitted to the Exchange a copy of Information under Clause 20(b) of the Listing Agreement for the year ended March 31, 2012.

Wyeth Limited has informed the Exchange that Mr. Kewal Handa, Managing Director has intimated the Board of Directors of the Company of his intention to step down as Managing Director and Director of the Company in August 2012.

Wyeth Limited has informed the Exchange that: "Wyeth Limited ("the Company") has been informed by Wyeth (its parent company) of the merger of the latter corporation, with Wagner Acquisition Corp., a direct, wholly-owned subsidiary of PFizer Inc., through a scheme of merger effected pursuant to and as per the prevailing laws of the United States of America. The merger of Wyeth and Wagner Acquisition Corp. has become effective as on October 15, 2009 and as a result of the merger, Pfizer Inc. is now the parent company of Wyeth and hence the ultimate parent of the Company".

Wyeth Limited has informed the Exchange regarding the status of litigation under the Drugs (Prices Control) Order, 1979- DMCTC. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Wyeth_Upd_300620089.zip target=NEW> For more details click here.</a>